The first work that examined the ability of cystatin-C to predict mortality in these patients was published by Shlipack et al. [13], who analyzed a subgroup of 279 patients with prevalent HF from the Cardiovascular Health Study. The gene discussed is CST3; the disease is hydrops fetalis.